Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Inflammation
Filter     Order     Display # 
Date Item Title Hits
26 Aug 2010 Swedish Orphan Biovitrum's Kineret(R) has Received Orphan Drug Designation in the USA 5
26 Aug 2010 Chelsea Therapeutics Announces FDA Approval of CH-4051 Phase II Protocol 6
26 Aug 2010 Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I 5
24 Aug 2010 Isotechnika Pharma and 3SBio Announce Strategic Partnership to Develop and Commercialize Voclosporin in China 5
23 Aug 2010 Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote Supplemental New Drug Application 25
20 Aug 2010 SkyePharma regains United States marketing rights to Flutiform 11
20 Aug 2010 Protalex, Inc. Announces Dosing of First Patient in a Phase 1b Study of PRTX-100 in Patients With Active Rheumatoid Arthritis 10
19 Aug 2010 Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus 11
13 Aug 2010 NICE concludes omalizumab is not an effective use of NHS resources for children under 12 12
12 Aug 2010 BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteochondritis Dissecans 14
10 Aug 2010 Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis 14
06 Aug 2010 Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK 10
06 Aug 2010 Vectura and GlaxoSmithKline sign agreement to license some of Vectura’s dry powder drug formulation patents 12
04 Aug 2010 ACTEMRA Humanized Anti-Human IL-6 Receptor Monoclonal Antibody 17
02 Aug 2010 N30 Pharma Announces FDA Approval to Initiate Phase 1 Clinical Trial for First-in-Class Drug 13
31 Jul 2010 FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin) 21
29 Jul 2010 Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS) 17
28 Jul 2010 DiaMedica Announces Autoimmune Program With Positive Rheumatoid Arthritis Results 20
28 Jul 2010 Limerick BioPharma Announces Positive Phase 1b Data for LIM-0705 in Preventing Toxicities Associated with the Transplant Drug, Tacrolimus 23
28 Jul 2010 Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 20
27 Jul 2010 ProtAffin AG Signs Manufacturing Contract for PA401 with CMC Biologics A/S 12
23 Jul 2010 Unigene Reports Continuation of Phase III Study of Oral Calcitonin in Osteoarthritis Patients 19
23 Jul 2010 Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis 15
22 Jul 2010 FDA provides Complete Response Letter to NicOx's New Drug Application for naproxcinod 22
21 Jul 2010 Prochymal New Drug Submission Granted Priority Review by Health Canada 14
13 Jul 2010 Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA, a Potential New Treatment for Systemic Lupus Erythematosus 22
08 Jul 2010 Western States Biopharmaceuticals and University of Colorado Announce Exclusive Licensing Agreement for TCISM Targets to Treat Autoimmune Diseases 99
07 Jul 2010 NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36 21
07 Jul 2010 European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis 56
06 Jul 2010 Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform 23
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1351

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics